The threat of imminent generic competition in the US to Novartis AG’s big-selling multiple sclerosis pill Gilenya has all but disappeared after a court upheld its patent and blocked a version developed by China's HEC Pharma.
The Swiss major has revealed that a US court of appeals has upheld the validity of a dosing regimen patent...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?